Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Galena Biopharma Inc    

 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 -
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
Sales 2018 -
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 0
Capitalization 21,3 M
More Financials
Company
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs.The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment... 
Sector
Pharmaceuticals
Calendar
05/11Earnings Release
More about the company
Latest news on GALENA BIOPHARMA INC
03/23 GALENA BIOPHARMA, INC. (NASDAQ : GALE) Files An 8-K Departure of Directors or Ce..
03/23 GALENA BIOPHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
03/23 Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Bi..
03/23 GALENA BIOPHARMA INC : Khang & Khang LLP Announces Securities Class Action Lawsu..
03/23 GALENA BIOPHARMA INC : Bronstein, Gewirtz & Grossman, LLC Reminds Investors of C..
03/17 GALENA BIOPHARMA INC : Pawar Law Group Announces Filing of Securities Class Acti..
03/17 Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical T..
03/16 Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopha..
03/16 GALENA BIOPHARMA INC : Lundin Law PC Announces Securities Class Action Lawsuit a..
03/16 GALENA BIOPHARMA INC : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Re..
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
Latest Tweets
03/10Bay Area's Galena Biopharma Exploring Strategic Alternatives Just One Month A.. 
03/09$GALE- Galena Biopharma Engages Canaccord Genuity to Advise on Strategic Alte.. 
03/03Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Ga.. 
02/21BRIEF-Galena Biopharma board appoints Stephen Ghiglieri as interim CEO  
02/21Galena Biopharma Board of Directors Appoints Stephen F. Ghiglieri as Interim .. 
More tweets
Qtime:12
News from SeekingAlpha
2016 Galena Biopharma's (GALE) CEO Mark Schwartz on Q3 2016 Results - Earnings Cal..
2016 Galena Biopharma beats by $0.02
2016 Notable earnings after Wednesday?s close
2016 RXI PHARMACEUTICALS : Moving On Promising Scar Treatment
2016 Best And Worst Performing Stocks Of 2016
Advertisement
Chart GALENA BIOPHARMA INC
Duration : Period :
Galena Biopharma Inc Technical Analysis Chart | US3632561086 | 4-Traders
Full-screen chart
Technical analysis trends GALENA BIOPHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 3
Average target price 8,00 $
Spread / Average Target 1 249%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stephen F. Ghiglieri CEO, Chief Financial & Accounting Officer
Sanford J. Hillsberg Chairman
Bijan Nejadnik Chief Medical Officer & Executive Vice President
Stephen S. Galliker Independent Director
Rudolph Nisi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GALENA BIOPHARMA INC-87.52%21
JOHNSON & JOHNSON8.91%341 301
ROCHE HOLDING LTD.8.60%219 164
PFIZER INC.4.68%204 201
NOVARTIS AG-0.94%196 550
MERCK & CO., INC.7.32%173 740
More Results